Marshall Wace, LLP Castle Biosciences Inc Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Castle Biosciences Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 212,036 shares of CSTL stock, worth $5.91 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
212,036
Previous 97,932
116.51%
Holding current value
$5.91 Million
Previous $2.17 Million
112.82%
% of portfolio
0.01%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CSTL
# of Institutions
171Shares Held
25.5MCall Options Held
511KPut Options Held
130K-
Black Rock Inc. New York, NY3.04MShares$84.8 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT2.33MShares$64.9 Million0.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$43.9 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.5MShares$41.7 Million0.02% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.22MShares$33.9 Million0.44% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $733M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...